Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: March Update

Performance overview
Value at beginning of month: $151,976.63
Value at end of month: $147,509.10
Month over month change: -2.94%
Total IRR: 37.83%

Related indices, monthly change
NASDAQ: -3.73%
IVV (iShares Core S&P 500): -3.67%
IBB (iShares NASDAQ Biotechnology Index): -3.56%
MXI (iShares Global Materials): -5.49%
VEGI (iShares MSCI Global Agriculture Producers): -3.89%
ICLN (iShares Clean Energy):+0.63%

Individual performances


Arcadia Biosciences had a huge month, quadrupling in price after hitting key milestones in their wheat development programs. Other agricultural biotech companies Yield10 and AquaBounty were also up on this news. Overall, many therapeutic companies had a very rough month, which led to an overall decline in the index. Calyxt, which makes up 15% of the index, also showed heavy declines.

Changes made to index

Added Synlogic, a company developing living medicines, which went public in March through a reverse-merger. Removed all companies who had made up less than 0.10% of the index - Applied Genetic Technologies Corporation, Bioamber, Fibrocell Science, Krystal Biotech - and Juno Therapeutics, which was acquired.

You can view the index here.

Allocation as of March 23, 2018


Calvin Schmidt Synthetic Biology Index: April Update

Calvin Schmidt Synthetic Biology Index: February Update